Cancel the denosumab holiday

This publication has 58 references indexed in Scilit:

• Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
  Journal of Bone and Mineral Research, 2012
• The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
  Journal of Bone and Mineral Research, 2011
• Hip fracture in postmenopausal women after cessation of hormone therapy
  Menopause, 2011
• Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
  Osteoporosis International, 2011
• Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy
  JAMA, 2011
• Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
  New England Journal of Medicine, 2009
• Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
  New England Journal of Medicine, 2009
• Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
  Bone, 2008
• Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy
  JAMA, 2004
• BONE RESPONSE TO TERMINATION OF ŒSTROGEN TREATMENT
  The Lancet, 1978